2
Participants
Start Date
September 28, 2023
Primary Completion Date
July 17, 2025
Study Completion Date
July 17, 2025
Trastuzumab deruxtecan
"All patients enrolled will be treated with trastuzumab deruxtecan (T-DXd) 5.4 mg/kg IV every 3 weeks (± 3 days).~The subject's weight at baseline will be used to calculate the initial dose. If during the course of treatment the subject's weight changes by ± 10% of the baseline weight, the subject's dose will be recalculated based on the subject's updated weight.~Patients will receive T-DXd until unacceptable toxicity, progressive disease (PD), informed consent withdrawal, or other discontinuation criterion is met."
Hospital Universitario San Pedro de Alcántara, Cáceres
Hospital Universitario de Jeréz De La Frontera, Cadiz
Complejo Hospitalario Universitario A Coruña (CHUAC), A Coruña
Hospital Universitario Clínico San Cecilio, Granada
Hospital Universitario de Jaén, Jaén
Hospital Universitario Arnau de Vilanova de Lleida, Lleida
Hospital General Universitario Gregorio Marañón, Madrid
Hospital Universitario Ramón y Cajal, Madrid
Hospital Universitario 12 de Octubre, Madrid
Hospital Universitario La Paz, Madrid
Hospital Universitario Puerta de Hierro de Majadahonda, Majadahonda
Hospital Universitario de Fuenlabrada, Fuenlabrada
Hospital Universitario Marqués de Valdecilla, Santander
Hospital Universitario Virgen del Rocío, Seville
Hospital Galdakao-Usansolo, Galdakao
Hospital Universitario Son Espases, Palma de Mallorca
Hospital San Juan de Alicante, Alicante
Hospital Universitario de Badajoz, Badajoz
Hospital del Mar, Barcelona
Collaborators (1)
AstraZeneca
INDUSTRY
Spanish Breast Cancer Research Group
OTHER